Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
rabeprazole (rabeprazole sodium)
KRKA d.d.
A02BC04
rabeprazole (rabeprazole sodium)
20mg
tablets gastro-resistant
(28/2x14/) in blister, (56/4x14/) in blister
Prescription
Registered
2020-10-14
Summary of product characteristics CONFIDENTIAL Zulbex gastro-resistant tablets 10 mg, 20 mg MODULE 1 VOL: 1; P: 25 / 271 1.3.1 Rabeprazole sodium SPC, Labeling and Package Leaflet AM SmPCPIL137288_1 05.09.2019 – Updated: 05.09.2019 Page 1 of 10 1. NAME OF THE MEDICINAL PRODUCT Zulbex ® 10 mg gastro-resistant tablets Zulbex ® 20 mg gastro-resistant tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Zulbex 10 mg gastro-resistant tablets Each gastro-resistant tablet contains 10 mg rabeprazole sodium equivalent to 9.42 mg rabeprazole. Zulbex 20 mg gastro-resistant tablets Each gastro-resistant tablet contains 20 mg rabeprazole sodium equivalent to 18.85 mg rabeprazole. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Gastro-resistant tablet 10 mg gastro-resistant tablets are round, biconvex, orange pink film coated tablets with bevel edges. 20 mg gastro-resistant tablets are round, biconvex, slightly brownish yellow film coated tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zulbex tablets are indicated for the treatment of: Active duodenal ulcer Active benign gastric ulcer Symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD) Gastro-oesophageal reflux disease long-term management (GORD maintenance) Symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic GORD) Zollinger-Ellison syndrome In combination with appropriate antibacterial therapeutic regimens for the eradication of _Helicobacter pylori_ in patients with peptic ulcer disease. See section 4.2. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults/elderly: _Active duodenal ulcer and active benign gastric ulcer: _The recommended oral dose for both active duodenal ulcer and active benign gastric ulcer is 20 mg to be taken once daily in the morning. Most patients with active duodenal ulcer heal within four weeks. However, a few patients may require an additional four weeks of therapy to achieve healing. Most patients with active benign gastric ulcer heal wi Read the complete document